All In Biotech

BLA 761139 · Daiichi Sankyo

Enhertu

Fam-Trastuzumab Deruxtecan-Nxki · Injection

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Dec 20, 2019

Approved uses

14

Original approval plus efficacy supplements

Registered trials

27

2 Phase 3, 20 recruiting

FAERS reports

10,910

8,277 serious, 2,791 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY Interstitial Lung Disease (ILD) and pneumonitis, including severe, life-threatening, and fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and the need to immediately report symptoms [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) ] . Embryo-Fetal Toxicity: Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception [see Warnings and Precautions (5.4) , Use in Specific Populations (8.1 , 8.3) ] . WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY See full prescribing...

What it is approved for

From the label in effect May 15, 2026.

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for: HER2-Positive Early Breast Cancer as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test followed by a taxane, trastuzumab, and pertuzumab (THP). ( 1.1 ) as adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment. ( 1.1 ) HER2-Positive Metastatic Breast Cancer in combination with pertuzumab as first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an FDA-authorized test. ( 1.2 ) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or, in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. ( 1.2 ) HER2-Low and HER2-Ultralow Metastatic Breast Cancer as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting. ( 1.3 ) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic setting; or developed...

Mechanism: Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to HER2 on tumor cells, fam-trastuzumab deruxtecan-nxki undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 15, 2026 Supplement 43 · Efficacy · priority review Breakthrough therapyOrphanLetterLabelMedication Guide
  • May 15, 2026 Supplement 41 · Efficacy OrphanLetterLabelMedication Guide
  • Apr 27, 2026 Supplement 39 · Efficacy OrphanLabelLetter
  • Dec 15, 2025 Supplement 38 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Jan 27, 2025 Supplement 32 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Apr 5, 2024 Supplement 28 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Feb 15, 2024 Supplement 26 · Efficacy OrphanLabelLetter
  • Nov 4, 2022 Supplement 24 · Efficacy · priority review LabelLetter
  • Aug 11, 2022 Supplement 21 · Efficacy · priority review Breakthrough therapyLabelLetterReview
  • Aug 5, 2022 Supplement 22 · Efficacy · priority review Breakthrough therapyLetterLabel
  • May 4, 2022 Supplement 20 · Efficacy · priority review Breakthrough therapyLabelLetter
  • May 4, 2022 Supplement 17 · Efficacy · priority review LabelLetter
  • Jan 15, 2021 Supplement 11 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Dec 20, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
  • ENHERTU · FAM-TRASTUZUMAB DERUXTECAN-NXKI 100MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fam-Trastuzumab Deruxtecan" as an intervention, any sponsor and status, largest first.

All 27 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,336
  • nausea1,288
  • disease progression1,257
  • interstitial lung disease1,100
  • fatigue858
  • off label use846
  • diarrhoea632
  • vomiting593
  • pneumonitis441
  • decreased appetite410
  • asthenia407
  • no adverse event381

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20194
2020380
2021717
20221,274
20231,808
20242,028
20252,248
20262,450

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Enhertu (Fam-Trastuzumab Deruxtecn-Nxki)

2024 spending

$10.6M

Beneficiaries

171

1,011 claims

Per beneficiary

$62,221

$2,588.75 per unit

View as table
YearSpending
2020$1,410,930
2021$3,350,096
2022$4,311,977
2023$10,228,153
2024$10,639,779

Part B: Enhertu (Fam-Trastuzumab Deruxtecn-Nxki) · HCPCS J9358

2024 spending

$581M

Beneficiaries

8,410

56,172 claims

Per beneficiary

$69,140

2024 ASP limit $27.54 per unit

View as table
YearSpending
2020$37,181,509
2021$109,118,974
2022$257,875,575
2023$464,747,799
2024$581,465,185

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Daiichi Sankyo

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.